Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
NEW YORK, Feb. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/aratana-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
